BioGeometry, the Beijing AI protein-design startup founded by Jian Tang, an associate professor at HEC Montréal and a core academic member at Mila, has closed a Series A+ round led by China Life Capital, bringing its combined Series A funding above $100 million, according to coverage of the company's Oct. 28 announcement.
Neither the company nor its investors disclosed the size of the A+ tranche or the startup's valuation, Peptide & Protein reported. Outlets including 36Kr, Sina Finance and Dealroom News each put the cumulative Series A total at more than $100 million.
A Mix of Institutional and Existing Backers
Besides China Life Capital, the round drew Shanghai Biomedical Fund, CDB Kechuang, Ruili Investment and Guofang Capital. 36Kr also cited "leading biopharma industry parties," without naming them. Fortune Capital (Dachen), an existing investor, put in more money, and Index Capital again acted as exclusive financial advisor.
"We are very pleased to lead the Series A+ financing of BioGeometry," China Life Capital said in a statement carried by 36Kr.
Qiushan Guo, a partner at Shanghai Biomedical Fund, told 36Kr that the fund's involvement had been steady: "From joint lead in the first round to continued investment this round, our judgment… has been consistently validated."
The Path to This Round
The A+ follows a strategic round announced June 30, 2026, which the company described only as "hundreds of millions of RMB." Shanghai Biomedical Innovation & Translation Fund, CAS Investment, Fortune Capital and Link-X Capital co-led that financing, and Gaorong Capital and the Index AI Industry Innovation Fund took part. Earlier still, on Nov. 1, 2022, the company announced an angel round without naming its investors.
Where the Money Goes
Per 36Kr, Sina Finance, Peptide & Protein and Dealroom News, proceeds will fund further development of two models. GeoFlow is what the company calls an all-atom biomolecular "world model," meaning one that aims to represent proteins and related molecules at the level of individual atoms. GeoCell is a cell-level "virtual cell" model. The startup also plans to expand its automated high-throughput labs and push ahead its in-house drug pipelines. Peptide & Protein reported that several bispecific antibodies, which are engineered to bind two different targets, are slated to reach investigational new drug (IND) filings in 2027.
Performance Claims, Largely Unverified
The company said GeoFlow V3 reached a hit rate of nearly 20% across more than 20 targets, with lead discovery cycles under three weeks. In an October 2025 post, it reported a 15.5% average wet-lab hit rate across eight de novo campaigns, referring to experiments that start from newly designed molecules. All of these figures come from the company, and the research did not independently verify them.
In June, BioGeometry also said it was a "core contributor" to NVIDIA's La-Proteina model. NVIDIA's pages do not list BioGeometry among the authors, so the claim rests on the company's word. On Aug. 31, 2026, the startup announced a strategic collaboration with GenScript to build functional protein annotation data for model training.
Team and Competitive Field
Tang is an associate professor at HEC Montréal, a core academic member at Mila and a Canada CIFAR AI Chair. According to the company's About page, he previously worked as an associate researcher at Microsoft Research Asia. Yoshua Bengio, the 2018 Turing Award winner and Mila's founder, is listed as chief scientific advisor.
Founded in 2022, BioGeometry has offices in Beijing and a research and development center in Shanghai. The third-party directory vbdata.cn lists its headcount at 15 to 50, though the company has not confirmed that range.
Dealroom News said capital is concentrating in a narrow set of AI drug-discovery players in China in 2026, and described BioGeometry's round as part of that trend. Elsewhere, Stipple Bio announced a $100 million Series A on April 6, 2026, for protein-focused oncology. William Blair's research names Nabla Bio and Profluent among AI-first protein design companies.
For BioGeometry, the next test is clinical. The company expects several bispecific antibodies to reach IND filings in 2027.
